PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study

BACKGROUND: The aim of this study was to assessment the efficacy and safety of Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shubin, Wei, Haowen, Zhao, Wenhua, Jiang, Wei, Ning, Ruiling, Zhou, Shaozhang, Tan, Liping, Wang, Huilin, Su, Cuiyun, He, Jianbo, Zeng, Aiping, Zhao, Yun, Yu, Qitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767946/
https://www.ncbi.nlm.nih.gov/pubmed/36569915
http://dx.doi.org/10.3389/fimmu.2022.1059995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767946/
https://www.ncbi.nlm.nih.gov/pubmed/36569915
http://dx.doi.org/10.3389/fimmu.2022.1059995

Ejemplares similares